NCT02152982

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2014-12-15Est. Completion: 2021-12-01

Enrollment target: 447 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Katmai Oncology Group, Anchorage, Alaska, United States
Providence Alaska Medical Center, Anchorage, Alaska, United States
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
Mills-Peninsula Medical Center, Burlingame, California, United States
John Muir Medical Center-Concord, Concord, California, United States
Kaiser Permanente-Fremont, Fremont, California, United States
Fresno Cancer Center, Fresno, California, United States
Kaiser Permanente-Fresno, Fresno, California, United States
Saint Jude Medical Center, Fullerton, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States

Brain (Nervous System) Cancers

This research study is for participants with glioblastoma. It can cause a tumor immunosuppression which helps myeloid ce…

Cleveland, United StatesEst. completion Dec 17, 2027

MTAP-deleted Solid Tumors

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid t…

Birmingham, United StatesEst. completion Jun 18, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.